Hoth Therapeutics shares surge 10.36% intraday after Chinese patent granted for mast cell-targeting technology.

Hoth Therapeutics surged 10.36% intraday following the announcement that the China National Intellectual Property Administration granted a patent for its splice-switching oligonucleotide technology, which selectively induces apoptosis in mast cells. The patent, developed in collaboration with North Carolina State University, expands Hoth's IP portfolio in a key global market and supports its focus on therapies for inflammatory, immunological, and oncological conditions. The company highlighted the strategic importance of the patent in strengthening its competitive position and advancing its pipeline. The news reinforced investor confidence in Hoth's long-term potential, particularly given its early-stage clinical candidates and strong balance sheet, contributing to the sharp intraday gain.